Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Co. focuses on targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are vital to normal and effective function of the brain and nervous system. Co. is developing a pipeline of product candidates derived from its NMDAr modulator discovery platform, or the discovery platform: NYX-2925 for the treatment of chronic pain; NYX-783 for the treatment of post-traumatic stress disorder; and NYX-458 for the treatment of cognitive impairment. The APTX average annual return since 2018 is shown above.
The Average Annual Return on the APTX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether APTX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the APTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|